Key facts
- Scarlet Therapeutic’s last known valuation is $7.4M (Feb 2026).
- It has raised $3.9M; the latest was Early Stage VC ($1.5M) in Feb 2026.
- Notable investors include Innovate UK, Meltwind Advisory, University of Bristol, SCVC, Science Creates.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Scarlet Therapeutic
- ·The full record, as it builds
Funding rounds
No funding rounds for Scarlet Therapeutic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scarlet Therapeutic
Developer of a healthcare platform that generates red blood-based therapeutics intended to treat a wide range of diseases. The company's cells carry additional proteins within them to provide a therapeutic benefit and pervasive reach throughout the body and can be used in the treatment of diseases such as hyperammonemia, hyperoxaluria, other metabolic diseases, cancer, and autoimmune diseases, enabling the healthcare industry to treat diseases with more efficacious therapies.
- Sector
- Healthcare
- HQ
- Bristol, United Kingdom
- Founded
- 2021
- Employees
- 8
- Website
- scarlet-tx.com/
- Ownership
- Privately Held (backing)
Scarlet Therapeutic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scarlet Therapeutic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scarlet Therapeutic in its N-PORT filings yet. We sweep new filings monthly.